Company Description
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma.
Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors.
It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib.
The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024.
Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jan 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Nadim Ahmed |
Contact Details
Address: One Main Street, Suite 1350 Cambridge, Massachusetts 02142 United States | |
| Phone | 617 410 4650 |
| Website | cullinantherapeutics.com |
Stock Details
| Ticker Symbol | CGEM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $21.00 |
| CIK Code | 0001789972 |
| CUSIP Number | 230031106 |
| ISIN Number | US2300311063 |
| Employer ID | 81-3879991 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nadim Ahmed | President, Chief Executive Officer and Director |
| Dr. Jeffrey Jones M.B.A., M.D., M.P.H. | Chief Medical Officer |
| Dr. Patrick A. Baeuerle Ph.D. | Co-Founder, Chief Scientific Advisor and Chairman of Scientific Advisory Board |
| Mary Kay Fenton CPA | Chief Financial Officer |
| Dr. Jennifer Michaelson Ph.D. | Chief Scientific Officer |
| Jacquelyn L. Sumer J.D. | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary |
| Steve Andre | Chief Human Resources Officer |
| Dr. Corinne Savill Ph.D. | Chief Business Officer |
| Rose Weldon | Senior Vice President of Corporate Affairs |
| Kevin A. Johnston | Chief Technical Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Jan 29, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |